Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study

BMJ Open

Volumn 8, Issue 4, 2018, Pages

  Vallejo Torres, Laura ^a,b   Pujol, Miquel ^c,d   Shaw, Evelyn ^c,d   Wiegand, Irith ^e   Vigo, Joan Miquel ^f   Stoddart, Margaret ^g   Grier, Sally ^g   Gibbs, Julie ^g   Vank, Christiane ^e   Cuperus, Nienke ^h   Van Den Heuvel, Leo ^h   Eliakim Raz, Noa ^i,j   Carratala, Jordi ^c,d   Vuong, Cuong ^e   Macgowan, Alasdair ^g   Babich, Tanya ^i,j   Leibovici, Leonard ^i,j   Addy, Ibironke ^e   Morris, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e AiCuris GmbH   (Germany)

^f Fundacion Institut Catala de Farmacologia   (Spain)

^g SOUTHMEAD HOSPITAL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ RABIN MEDICAL CENTER   (Israel)

^j TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

cost of illness; health economics; urinary tract infections

Indexed keywords

AGED; ANTIBIOTIC THERAPY; ARTICLE; BLADDER CATHETERIZATION; BULGARIA; CATHETER INFECTION; CHARLSON COMORBIDITY INDEX; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; GREECE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HUNGARY; INFECTION COMPLICATION; ISRAEL; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; OUTPATIENT; RETROSPECTIVE STUDY; RISK FACTOR; ROMANIA; SEPSIS; SEPTIC SHOCK; SPAIN; TURKEY (REPUBLIC); URINARY TRACT INFECTION; CLINICAL TRIAL; ECONOMICS; GRAM NEGATIVE INFECTION; HOSPITALIZATION; ISOLATION AND PURIFICATION; MAGNET; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; TURKEY (BIRD); VERY ELDERLY;

ANTIINFECTIVE AGENT;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BULGARIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HUNGARY; ISRAEL; ITALY; MAGNETS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; ROMANIA; SPAIN; TURKEY; URINARY TRACT INFECTIONS;

EID: 85052301582     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-020251     Document Type: Article

References (26)

1. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis Rep 2008;10:499-504.
2. Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997;53:583-92.
3. Levison ME, Kaye D. Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr Infect Dis Rep 2013;15:109-15.
4. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5S-13.
5. European Centre for Disease prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: European Centre for Disease prevention and Control, 2013.
6. Cassini A, Plachouras D, Eckmanns T, et al. Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med 2016;13:e1002150.
7. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents 1999;11:247-51.
8. Foxman B, Barlow R, D'Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10:509-15.
9. François M, Hanslik T, Dervaux B, et al. The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey. BMC Health Serv Res 2016;16:365.
10. Ciani O, Grassi D, Tarricone R. An Economic Perspective on Urinary Tract Infection: The Costs of Resignation. Clin Drug Investig 2013;33:255-61.
11. Tambyah PA, Knasinski V, Maki DG. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol 2002;23:27-31.
12. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am J Infect Control 2000;28:68-75.
13. Cardwell SM, Crandon JL, Nicolau DP, et al. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract 2016;44:33-40.
14. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med 2014;9:232-8.
15. Esteve-Palau E, Solande G, Sánchez F, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. J Infect 2015;71:667-74.
16. Shaw E, Addy I, Stoddart M, et al. Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). BMJ Open 2016;6:e011500.
17. U.S. Department of Health and Human Services Food and Drug Administration. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry, 2015. https://www. fda. gov/ downloads/ Drugs/./ Guidances/ ucm070981. pd.f.
18. Roberts RR, Scott RD, Hota B, et al. Costs attributable to healthcareacquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010;48:1026-35.
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
20. Turner RM, Wu B, Lawrence K, et al. Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections. Clin Ther 2015;37:2037-47.
21. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010;122:7-15.
22. World Health Organization. WHO-Choice unit cost estimates for service delivery. 2011 http://www. who. int/ choice/ country/ WHOCHOICEunit- cost- estimates- 2007- 2008. xl.s.
23. Ahmed NH, Hussain T, Biswal I. Comparison of etiological agents and resistance patterns of the pathogens causing community acquired and hospital acquired urinary tract infections. J Glob Infect Dis 2014;6:135-6.
24. Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection 2012;18:268-81.
25. OECD. Health at a Glance 2017: OECD Indicators. Paris: OECD Publishing, 2017.
26. Stewardson AJ, Harbarth S, Graves N. Valuation of hospital beddays released by infection control programs: a comparison of methods. Infect Control Hosp Epidemiol 2014;35:1294-7.